1. Generics Bulletin
  2. >>Products

Henlius Denosumab Biosimilar Trial Enters Phase III

As Firm’s Shanghai Plant Has Received EU GMP Equivalence

 
• By Chloe Kent

Henlius has administered the first dose in its international Phase III trial into its denosumab biosimilar candidate, HLX14. The firm has also revealed that its new Songjiang plant has been granted GMP equivalence with EU practices.

Osteoporosis
The study will evaluate the impact of Henlius' candidate on bone mineral density. • Source: Shutterstock

The first subject has been dosed in Shanghai Henlius Biotech’s international multicenter Phase III clinical trial for HLX14, its proposed biosimilar to Amgen’s Prolia/Xgeva (denosumab), for the treatment of postmenopausal osteoporosis in women with high fracture risks.

The randomized, double-blind, international multicenter, parallel-controlled Phase III study aims to compare the efficacy, safety, tolerability and immunogenicity of HLX14 with reference denosumab. Patients will be randomized 1:1 to receive either a subcutaneous injection of HLX14 or reference denosumab every six months for two cycles

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.